Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers

This study tests whether combining cryoablation (a procedure that freezes and destroys tumors) with an immunotherapy drug (camrelizumab) and a targeted therapy (apatinib) can help treat people with multiple lung cancers — specifically those who have more than 2 small lung nodules remaining after previous surgery. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with multiple primary lung cancers - You have at least 3 lung nodules at diagnosis or before surgery, with no spread to lymph nodes - The largest nodule is 3 cm or smaller - After previous lung surgery, at least 2 nodules remain, confirmed as minimally invasive or in-situ lesions - You are in good general health (ECOG performance score 0–1) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - Your nodules are larger than 3 cm - You have lymph node involvement - You do not meet minimum blood count and organ function requirements Talk to your doctor to see if this trial is right for you.